A groundbreaking new trial is set to investigate whether an mRNA jab, designed to target the Epstein-Barr virus (EBV), could offer a novel treatment pathway for multiple sclerosis (MS).
Scientists are exploring this avenue given that EBV, commonly known for causing glandular fever, is present in almost all individuals with MS and is believed to play a significant role in the condition's development.